Nebularine, a Natural Adenosine Analog, Modulates Cell Cycle Progression, Migration, and Survival in Breast Cancer Cells: Integrating In Vitro Findings with In Silico Transcriptomic Analysis
Breast cancer remains a highly heterogeneous malignancy, accounting for nearly one-third of female cancers worldwide; thus, there is an urgent need for novel selective agents to overcome treatment resistance and systemic toxicities. We investigated the selective antiproliferative, antimigratory, and pro-apoptotic mechanisms of Nebularine (NEB), a natural purine nucleoside analog, across breast cancer cellular models by integrating phenotypic and transcriptional responses with structural binding dynamics and clinical prognostic correlations. Cell viability and selective indices (SIs) were evaluated in breast cancer (MDA-MB-231 and MCF-7) and non-malignant human mammary epithelial (MCF-12A) cells using MTT assays across a 0–200 μM concentration range. Cellular motility was assessed via two-dimensional wound healing assays. Cell cycle kinetics and apoptotic populations were quantified using Annexin V/PI flow cytometry. qRT-PCR was performed to profile key cell cycle (CCNA2, CDK1, CDK2, CDKN1A/p21, CDKN1B/p27, and TP53) and apoptotic (BAX, BCL2L1/Bcl-XL, CASP9, and CASP3) transcripts. Structural interactions were investigated using AutoDock Vina molecular docking models. Clinical transcript expression and prognostic relevance were evaluated using TCGA/GTEx datasets via GEPIA2 and Kaplan–Meier survival analyses. NEB exerted moderate, dose-dependent antiproliferative activity, displaying an estimated IC50 of ~100 μM in aggressive MDA-MB-231 cells and IC50 > 200 μM in MCF-7 cells (57.93% viability at 200 μM), while non-malignant MCF-12A cells retained 99.75% viability at 200 μM (IC50 > 200 μM), yielding an in vitro selectivity index (SI) > 2.0. NEB treatment impaired two-dimensional wound closure in breast cancer cells without compromising baseline non-malignant cellular motility. Flow cytometry demonstrated prominent S-phase entrapment (accumulating up to 53.23%) alongside significant execution of apoptotic cell death. Transcriptional profiling revealed profound downregulation of key replication drivers (CCNA2 and CDK1) in both cancer lines, alongside p53-independent CDKN1A (p21) upregulation in MCF-7 cells. In silico docking predicted thermodynamically favorable structural compatibility with CDK1, Casp9, Bcl-XL, and Cyclin A2 (ΔG = −6.5 to −6.6 kcal/mol). Clinically, CCNA2 and CDK1 were overexpressed in BRCA primary tumors (p < 0.05) and portended poor survival, whereas elevated CASP9 expression correlated with extended overall and progression-free survival (p < 0.05). NEB acts as a selective purine nucleoside analog that triggers S-phase cell cycle arrest and apoptotic cell death in breast cancer models while demonstrating favorable selectivity over non-tumorigenic mammary epithelium. By transcriptionally suppressing pathologically elevated clinical drivers (such as CCNA2 and CDK1), NEB provides a promising structural template for further preclinical translational development.
Authors
- Pelin Telkoparan‐Akillilar (ORCID: https://orcid.org/0000-0003-0337-0763)
- Göksemin Fatma Şengül
- Fadime Kıran (ORCID: https://orcid.org/0000-0002-4536-2959)
- Naz Dizeci (ORCID: https://orcid.org/0000-0002-7366-1569)
- Özlem YILDIRIM (ORCID: https://orcid.org/0000-0002-7529-9786)
Institutions
- Ankara University (TR)
- Ankara Medipol Üniversitesi (TR)
- Gazi University (TR)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/ijms272210397
- Primary Topic
- Biochemical and Molecular Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00